Rapid vascular regrowth in tumors after reversal of VEGF inhibition.

By Michael R. Mancuso, Rachel B. Davis, Scott M. Norberg, S. O’Brien, B. Sennino, T. Nakahara, Virginia J. Yao, T. Inai, P. Brooks, B. Freimark and 3 more. Journal of Clinical Investigation, 2006

832 citations recorded by the source corpus.

Subfields: Cancer Research, Immunology and Allergy, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/7c8a63d9d9fb893c41fc2df3090d68d6513b7f06

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Immunology and Allergy

In Molecular Biology

Citations in the corpus

Molecular mechanisms and clinical applications of angiogenesis (2011, background): “Another hypothesis is that an angiogenesis rebound occurs after the arrest of anti-VEGF treatment, as documented in animal model”
Molecular regulation of angiogenesis and lymphangiogenesis (2007, background): “Because these structures favour the rapid regrowth of blood vessels when the VEGF signal is restored, matrix sleeves might be potential targets in cancer therap”
The biology of ovarian cancer: new opportunities for translation (2009, background): “Pericytes contribute to the maintenance of endothelial cell”
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis (2011, background): “There is also preclinical evidence for rapid revascularizatio”
Hypoxia: A key regulator of angiogenesis in cancer (2007, background): “The strong mitogenic effect of VEGF on endothelial cells was demonstrated by the application and subsequent withdrawal of VEGFR inhibitors in RIP-Tag2-transgenic mice [42].”
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions (2014, background): “Preclinical and clinical work shows that when VEGF-targeted therapy is discontinued, the tumour vasculature can become rapidly re-established [87, 88].”
Mechanisms of adverse effects of anti-VEGF therapy for cancer (2007, background): “I; Mancuso et al, 2006).”
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. (2008, background): “For instance, Mancuso and colleagues (34) reported that interfering with VEGF signaling alone reduces the number of endothelial cells in experimental tumors, with little effect on the associated vascular extracellular matrix and pericytes.”